April 24, 2020
– ALung gets EUA to Hemolung RAS for COVID-19
ALung has received FDA’s emergency use authorisation designation to the Hemolung respiratory assist system for treatment of COVID-19 patients.
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
April 24, 2020
– HCA Healthcare in COVID19 healed plasma study
172 of its affiliated hospitals are participating in a national study to test whether plasma from convalescent, or recovered, COVID-19 patients may help in the treatment of individuals currently sick from the virus.
April 24, 2020
– GlycoMimetics reports Q1 2020 results on May 1
ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its…
April 24, 2020
Lineage Cell Therapeutics sells $3.7M OncoCyte shares
announced the pricing of the sale of 1,672,689 shares of common stock of OncoCyte Corporation at a price to buyers of $2.27 per share, representing the closing price of OncoCyte common stock on April 23, 2020.
April 22, 2020
Dev. Health issues interest settlement securities
QUÉBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical corporation focused on…
April 22, 2020
Roche’s test to detect women at risk for cervical cancer gets FDA approval
Roche got approval from US Food and Drug Administration (FDA) for the cobas HPV test for use on the fully automated, high-throughput cobas 6800/8800 Systems which identifies women at risk for cervical cancer by detecting the presence of high-risk human papillomavirus (HPV) DNA in cervical samples.
April 22, 2020
Rocket Pharmaceuticals appoints Elisabeth Bjӧrk to board of directors
NEW YORK–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies…
April 22, 2020
Akili Announces ENDEAVORTM Digital Attention Treatment is Now Available for Children with Attention Deficit Hyperactivity Disorder (ADHD) under FDA’s COVID-19 Enforcement Discretion Guidance
BOSTON–(BUSINESS WIRE)–#ADHD—Akili today announced that ENDEAVORTM (AKL-T01) is now available for use by children with attention deficit hyperactivity disorder (ADHD)…
April 22, 2020
Actinium raises $27.5M
Actinium expects to raise $27.5 million to invest in its Sierra phase 3 trial, as well as other programs with…
April 20, 2020
Novartis picks up with Phase 3 testing hydroxycholoquine on COVID-19 disease patients
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease. The clinical trial drug supply will be provided by Sandoz, the generics and biosimilars division of Novartis.